ARS Pharmaceuticals (SPRY) Equity Average (2020 - 2026)

ARS Pharmaceuticals' Equity Average history runs 7 years deep, the most recent figure standing at $87.8 million for Q1 2026.

• In Q1 2026, Equity Average fell 63.86% year-over-year to $87.8 million; the TTM figure through Mar 2026 stood at $87.8 million (down 63.86% YoY), while the FY2025 annual figure was $185.5 million, down 23.9% from the prior year.
• Equity Average came in at $87.8 million for Q1 2026 at ARS Pharmaceuticals, down from $131.0 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $267.0 million in Q1 2023 to a low of -$47.1 million in Q3 2022.
• A 5-year average of $159.6 million and a median of $210.6 million in 2025 frame the typical range for Equity Average.
• Across the five-year window, Equity Average plunged 119.61% in 2022 and soared 868.14% in 2023, its largest moves.
• ARS Pharmaceuticals' Equity Average stood at $111.4 million in 2022, then soared by 110.14% to $234.0 million in 2023, then dropped by 2.19% to $228.9 million in 2024, then plunged by 42.79% to $131.0 million in 2025, then sank by 32.97% to $87.8 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $87.8 million, $131.0 million, and $170.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison